Experience with selegiline in the treatment of Parkinson's disease.

Abstract

28 patients with Parkinson's disease and long-term levodopa therapy have received additional selegiline (10 mg/d) over the past 3 years and been followed up for a mean period of 18.8 months. Two thirds improved with a reduction of global disability and amelioration of end-of-dose effects, nocturnal and early-morning akinesia. Peak-dose dyskinesias tended to increase with selegiline while biphase and off-period involuntary movements improved in some cases. Patients already on maximally tolerated doses of levodopa and those with severe on-off swings did not gain significant benefit. 8 of 18 responders lost their initial response within 1.5 years.

• Authors: W Poewe, F Gerstenbrand, G Ransmayr
• Journal: Journal of neural transmission. Supplementum (J Neural Transm Suppl) Vol. 25 Pg. 131-5 ( 1987) ISSN: 0303-6995 [Print] Austria
• PMID: 3123599 (Publication Type: Journal Article)

Chemical References

• Phenethylamines
• Selegiline

Topics

• Disability Evaluation
• Humans
• Parkinson Disease (drug therapy, physiopathology)
• Phenethylamines (therapeutic use)
• Retrospective Studies
• Selegiline (therapeutic use)
• Time Factors